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This is an opinion article based on the
paper “Clonotypic structures involved in
antigen-specific human T cell function.
Relationship to the T3 molecular complex”,
by Meuer S. C., Fitzgerald K. A., Hussey R.
E., Hodgdon J. C., Schlossman S. F., and
Reinherz E. L. (1).
Life and science do not necessarily fol-
low a straightforward path. So, it is not
surprising, in retrospect, that my decision
around Christmas of 1977 to terminate
my clinical hematology fellowship in favor
of a laboratory research associate position
at Dana-Farber Cancer Institute working
on lymphoid malignancies would result in
progress in basic immunology. Remark-
ably, however, the outcome of the research
yielded new insights into thymic develop-
ment, mature T-cell heterogeneity, and the
molecular basis for cognate recognition by
T lymphocytes.
At the time, my decision was moti-
vated by a clinical observation and desire
to understand its basis. Namely, if a physi-
cian treated 100 children with acute lym-
phoblastic leukemia (ALL) using the same
multi-agent chemotherapy, 80 of them
would go into remission and 20 of them
would die. I asked myself if that latter out-
come was 100% of 20% vs. 20% of 100%.
I thought that the answer might be the
former but sought the opinion of a clin-
ical mentor. He looked at me as if I had
three heads and simply commenting that
those who die have “poor protoplasm.”
This abject ignorance was so appalling and
annoying to me at the same time that I
quit on the spot. Since I had bluntly told
him what I thought of his response, I likely
would have been fired if I had not voluntar-
ily chosen to move on down the road quite
literally, as it were. While I had no explicit
experimental plans, it occurred to me that
antibodies raised against these tumor cells
might be capable of distinguishing subpop-
ulation heterogeneity, should it exist. After
all, in 1977, people were not distinguishing
red blood cells from different individuals
by holding them up to the light. In the
1920s, a man named Landsteiner sorted
out differences among RBCs that looked
alike through development of red blood cell
typing technology (2).
In any event, I moved to Dana-Farber
Cancer Institute to work with Stuart
Schlossman, who was Chief of the Division
of Tumor Immunology, which included
his own laboratory, that of Harvey Can-
tor, and several others. Stu enthusiastically
greeted me at the time. He was apprecia-
tive of my query since he, himself, was
trained as a hematologist and attempting
to dissect normal lymphoid heterogene-
ity. His laboratory already was generat-
ing rabbit antisera against various types
of hematopoietic cells. He told me that
he was just starting the production of
monoclonal antibodies (mAbs) using the
Kohler and Milstein method (3) and that I
might get involved. I retrieved human thy-
muses from children and neonates under-
going open heart surgery for congenital
cardiac abnormalities, peripheral T-cells
from normal volunteers isolated by sheep
erythrocyte rosetting (a way of fractionat-
ing human T-cells), and a host of leukemic
populations from my earlier patients. We
used human cells to immunize mice in
an effort to stimulate antibody produc-
tion. The combination of the species dif-
ferences as well as FACS-based screening
of B-cell hybridoma supernatants in lieu of
radioimunoassays employed by most other
groups permitted us to quickly identify
antibody targets, even when not expressed
at high levels on cells or restricted to a
subpopulation of those cells being inter-
rogated. As a consequence, it was rather
simple to derive mAbs against targets on
subpopulations of mature and immature T
lineage cells.
In 1979, we first identified the CD4 mol-
ecule, which we found to be expressed on
two-thirds of peripheral mature T lym-
phocytes with helper activity (4–6) and
then CD8 molecules expressed on the rec-
iprocal subset of T-cells, which manifest
most of the cytotoxic activity (7). In con-
trast, within the thymus itself, we origi-
nally described the major population of
thymocytes co-expressing CD4 and CD8,
which we termed double positive (DP)
as precursors of mature thymocytes (8).
In addition, we observed a small sub-
set of CD4−CD8− (double negative, DN)
thymocytes. The vast majority of ALLs
refractory to chemotherapy (those 20%
above) was derived from the DN thymo-
cytes (8). Susceptibility of this DN thy-
mocyte population to activating mutations
in NOTCH and aberrations of competi-
tive niches created during early develop-
ment are currently evolving as explanations
of thymocyte susceptibility [(9) and ref-
erences therein]. The fact is even without
detailed molecular understanding of these
immature ALLs and more mature T lin-
eage malignancies like acute lymphoblas-
tic lymphoma and Sezary syndrome, it
was obvious that such tumors represented
frozen states of normal T lineage develop-
ment. The notion that thymocyte devel-
opment progressed from DN to DP to
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SP (CD4+CD8− or CD4−CD8+) derived
from our studies. Acceptance of this idea
had to wait more than 4 years for the mouse
immunologists to create the anti-murine
CD4 mAb equivalent, L3T4 (10). The use
of these mAbs revolutionized mature T-cell
subset characterization in human beings
offering CD4/CD8 clinical ratios, absolute
CD4 counts, and the like. Comparative
analysis done with Lorenzo Loretta and
Max Cooper using other then currently
accepted methods revealed that the new
approach to define T lymphoid hetero-
geneity with mAbs was superlative to those
existing technologies (11).
In 1980, we first observed that the anti-
CD3 mAb could block antigen-specific
human T-cell proliferation to both solu-
ble antigens and alloantigens, as well as
inhibit generation of cytotoxic T-cells (12).
Of note, CD3 was expressed at latter stages
of thymic development but maintained on
all mature peripheral T-cells. Moreover,
antigen recognition by human T lympho-
cytes was linked to surface expression of the
CD3 molecular complex. When human T-
cell clones were incubated with anti-CD3
mAb at 37°C, there was a rapid and selec-
tive loss of CD3 expression and concomi-
tant antigen unresponsiveness (13). The
latter was not a generalized cellular inhi-
bition since IL-2 responsiveness remained
intact. Removal of anti-CD3 from cell cul-
ture mAb was followed by restoration of
T-cell surface CD3 expression and, in paral-
lel, return of antigen responsiveness. These
data set the stage for Ortho/Johnson &
Johnson Pharmaceuticals to develop OKT3
as a human immunosuppressive therapeu-
tic that was tested in treatment of allograft
transplant rejection and became the very
first FDA approved mAb in 1985 (14, 15).
Because research productivity went well,
I was promoted to Assistant Professor in the
Medicine Department at Harvard Medical
School in 1980. Baruj Benacerraf had both
taken over the helm of DFCI that year as
its president and won the Nobel Prize in
Physiology or Medicine in 1980 with Jean
Dausset and George Snell for “their dis-
coveries concerning genetically determined
structures on the cell surface that regulate
immunological reaction,” i.e., MHC. As a
newly minted faculty member, Baruj sum-
moned me to his office so that I could
describe to him the plans for my fledgling
research operation. I told Dr. Benacerraf
that all of my efforts were going to focus on
defining T-cell antigen recognition, includ-
ing identification of the T-cell receptor.
He told me that this goal was ambitious,
bold but probably ill advised. There were
too many established laboratories working
on this central immunological problem.
“What makes you think it’s likely that you
will succeed over them?” he queried. I
responded: “I’m looking for the receptor
on the surface of a T cell, not in culture
supernatants as the others are doing.” He
shrugged, wished me luck, and so the next
phase began. In the several years that fol-
lowed when success was achieved, it should
be noted that Baruj was laudatory and glad
I followed my scientific conviction.
In 1982, by exploiting T-cell cloning
techniques, first described by Smith and
colleagues (16), alloreactive CTL could be
derived from both human CD4 and CD8
subsets. Strikingly, CD4 T-cells recognized
MHC class II products, whereas CD8 T-
cells recognized MHC class I products.
These cells could be blocked by appropri-
ate anti-MHC I/II or anti-CD4 or anti-CD8
antibodies (17–22). Given that anti-CD3,
anti-CD4, and anti-CD8 mAbs all blocked
CTL activity, we wondered whether the sur-
face molecules identified by these mAbs
detected recognition elements or, alterna-
tively, components of the lytic machinery.
Lectin approximation studies excluded the
lytic machinery option since even in the
presence of the blocking antibodies, lectin
restored CTL function, although pointedly
with loss of target specificity.
The fact that biochemical analysis [see,
for example, in Ref. (23, 24)] failed to
identify differences in peptide maps or
electrophoretic mobility of these mole-
cules on human T-cell clones of differing
specificities argued that they were invari-
ant structures incapable of conferring anti-
gen and MHC specificities per se. Because
each cloned T lymphocyte recognizes anti-
gen in a precise fashion, one could not
account for its unique specificity on the
basis of monomorphic portions of CD3,
CD4, or CD8 (1). I reasoned that there
had to exist discriminative surface struc-
tures on individual clones, which we refer
to as clonotypes or idiotypes. mAbs to
such idiotypic structures (T idiotypic=Ti)
were produced next by immunizing mice
with CTL clones, screening the resulting
antibodies on the immunizing CTL and
then selecting those which lacked reac-
tivity with additional clones of differ-
ent antigen specificities from the same
donor (1, 25, 26). Such antibodies were
unique in that they inhibited cell-mediated
killing and antigen-specific proliferation of
the individual immunizing clone without
affecting the function of other autologous
clones. Moreover, like anti-CD3 mAbs, the
anti-clonotypic antibodies enhanced IL-2
responsiveness and induced modulation of
the Ti structure with CD3. Data showed
that the Ti clonotype was closely associ-
ated with CD3 in the membrane of human
T-cells. Immunoprecipitation and compet-
itive binding analysis revealed that the anti-
clonotypes defined a disulfide-linked het-
erodimer with α and β subunits of approx-
imately 49 and 43 kD, respectively. The
heterodimeric clonotype was not physi-
cally associated with CD4 or CD8 but
was in non-covalent association with the
invariant CD3 molecules as a complex first
evidenced by our analyses (1, 23, 25, 26).
From the above data collectively, I pro-
posed with my colleagues a working model
of T-cell cognate recognition (27) in which
the antigen binding structure comprised a
clonally unique αβ heterodimeric Ti moi-
ety in complex with CD3. The associative
recognition element is either CD4 or CD8
depending on the subset derivation of the
individual T lymphocyte. In this model,
CD4 and CD8 accessory (“co-receptor”)
glycoproteins bind to constant regions of
class II or class I MHC, respectively, which
are separate from the CD3-linked clono-
type. The TCR complex, on the other hand,
was defined as a CD3-associated Ti αβ het-
erodimer working in concert with CD4 and
CD8 to mediate MHC-restricted antigen
recognition. This view implied that there
was a bidentite interaction of the TCR
complex and co-receptor with the same
peptide/MHC. This proposal has been cod-
ified in structural studies over the last
30 years [for review, see Ref. (28)]. Confi-
dence that Ti was the αβ TCR heterodimer
encoding both peptide and MHC speci-
ficities came from (1) the unique abil-
ity of anti-clonotypic mAbs coupled to
Sepharose beads to trigger T-cell clones,
replacing requirements for cognate antigen
plus MHC (29); (2) biochemical evidence
for peptide variability within α and β sub-
units of Ti (30, 31), implying existence of
constant and variable regions as found in
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Ig heavy and light chains; (3) αβ purifica-
tion and amino acid sequencing showing
Ig homologies for each subunit (32, 33);
(4) the putative TCR triggering resulted in
T-cell proliferation via an IL-2-dependent
mechanism not observed by crosslinking
other T-cell structures (34); and (5) direct
evidence for the existence of nominal anti-
gen binding sites on Ti αβ heterodimers of
MHC-restricted T-cell clones specific for
fluorescein-5-isothiocyanate (35).
The work carried out over a period
of these several years was extraordinarily
exciting, converting concepts into explicit
molecular identities, beginning to explain
the complexities of T-cell recognition, pro-
viding reagents for clinical efforts and
fodder for considerable future structural
and molecular studies. These TCR efforts
required a spirited collection of colleagues
including Stefan Meuer who developed T-
cell clones and performed many functional
studies with Rebecca Hussey who made
the various mAbs used in the majority of
these studies, and Oreste Acuto who led
the biochemical charge on the TCR com-
plex and TCR αβ heterodimer purification
and amino acid sequencing with Marina
Fabbi. Bob Siliciano then showed that
the TCR αβ heterodimer actually bound
ligand.
Our efforts on TCR biology and its iden-
tification were complemented very soon by
studies in the mouse by Pippa Marrack
and John Kappler using T-cell hybridomas.
More explicitly, we published in JEM in
February 1983 on the first anti-clonotypic
mAb (1), while they published in the same
journal in April 1983 (36). Comparisons
of TCR αβ heterodimer clonotypes were
published by us in Nature in June 1983
and in PNAS in July 1983 (23, 25) whereas
their comparison appeared in Cell in Octo-
ber 1983 (37). We published on the abil-
ity of ant-clonotypic mAbs to replace the
requirement of peptide and MHC in T-cell
activation in September 1983, whereas our
competitors showed that anti-clonotypic
antibody binding to T-cell hybridomas pre-
dicted antigen and MHC specificity in
November 1983 (38). Furthermore, their
biochemical data matched well with that
of the human being and an independently
identified disulfide-linked T-cell tumor-
specific antigen identified with a mAb pro-
duced by Allison et al. (39). The human
being was a particularly informative and
tractable species choice since we had cre-
ated reagents that defined the TCR αβ het-
erodimer, CD3 components, and CD4 and
CD8 co-receptors. The majority of reagents
defining these receptors was lacking in the
mouse at the time. Biochemical detail by
Terhorst and Klausner further refined the
nature of the CD3 components of the TCR
complex (40, 41). The objective impact
of the three Reinherz, Marrack, and Alli-
son group efforts from the 1980 to 2000
time period is evident from ISI citations
(20,000 vs. 8,000 vs. 900, respectively).
In turn, molecular cloning of the TCR
subunits using a subtractive hybridization
method began (42–45). These studies iden-
tified TCRβ as shown by our subsequent
N-terminal amino acid sequencing analy-
sis (32). More than 30 years later, how-
ever, we are still in the process of detailing
structure and function of the TCR com-
plex and its co-receptors. The trove of
information herein will lead to important
therapeutic inventions for treatment of
autoimmune and immunodeficiency dis-
eases to be fully realized in the coming
years.
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